[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].

MLA

Morita, Yuka, et al. “[Polatuzumab Vedotin, Bendamustine, and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including the Outcome as a Bridging Treatment to CAR-T Cell Therapy or Allogeneic Hematopoietic Stem Cell Transplant].” [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, vol. 64, no. 7, 2023, pp. 586–95. EBSCOhost, https://doi.org/10.11406/rinketsu.64.586.

APA

Morita, Y., Yagi, Y., Kanemasa, Y., Sasaki, Y., Ishimine, K., Hayashi, Y., Mino, M., Ohigashi, A., Tamura, T., Nakamura, S., Okuya, T., Shimizuguchi, T., Shingai, N., Toya, T., Shimizu, H., Najima, Y., Kobayashi, T., Haraguchi, K., Doki, N., … Shimoyama, T. (2023). [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 64(7), 586–595. https://doi.org/10.11406/rinketsu.64.586

Chicago

Morita, Yuka, Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Kento Ishimine, Yudai Hayashi, Mano Mino, et al. 2023. “[Polatuzumab Vedotin, Bendamustine, and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including the Outcome as a Bridging Treatment to CAR-T Cell Therapy or Allogeneic Hematopoietic Stem Cell Transplant].” [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology 64 (7): 586–95. doi:10.11406/rinketsu.64.586.